Teva finds double-dose Copaxone halves side-effects

A 50% reduction in adverse side-effects was reported with the three-times-a-week 40 mg MS injection.

copaxone_05 TEVA

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has published results of a study showing less side effects in 40 mg doses of Copaxone injected three times a week as against 20 mg doses of the multiple sclerosis treatment injected daily.

The primary endpoint of the study, the adjusted mean annualized rate of injection-related adverse events (IRAEs), was achieved with a 50% reduction with the three-times-a-week 40 mg Copaxone versus the daily 20 mg regimen. In a post-hoc analysis, a similar reduction in moderate/severe IRAEs was observed with the less frequent, three-times-a-week Copaxone relative to the daily Copaxone.

Teva’s President of Global R&D and Chief Scientific Officer Dr. Michael Hayden said, “We’re pleased these results provide supportive data that fewer injections with three-times-a-week Copaxone 40 mg resulted in half as many reported IRAEs compared to the number of IRAEs with the Copaxone 20 mg once-daily dosing regimen.”

 

Read more about: , , , , , , , ,

Wordpress site Developed by Fixing WordPress Problems